Baycol Litigation
Baycol litigation has become widespread ever since the Baycol
recall was announced in August 2001. Since then, Bayer AG has
experienced dramatic rises and falls in its shares as the Baycol
litigation continues to play out. As analysts predicted Baycol
liability problems when a class action lawsuit was underway, shares
of Baycol halved. After a federal judge denied class action status,
the Baycol shares flew back up, but Baycol litigation is still
a very real problem for Bayer.
Bayer is still facing 11,000 pending Baycol claims, and most
of the Baycol litigation is alleged instances of rhabdomyolysis,
a rare and sometimes deadly disease causing kidney failure, muscle
damage, and other effects. Up until September 2003, the Baycol
litigation that had so far been resolved included Bayer paying
$477 million to settle out of court 1,342 U.S. Baycol lawsuits.
Legal experts have viewed the Baycol litigation as one of the
largest pharmaceutical recalls of present time.
This Baycol litigation mess has caused many people to remain
weary of any newly approved statin drugs. The latest cholesterol-
lowering drugs are having problems finding insurers to cover them
because of the side effects the drugs are associated to that mirror
Baycol litigation to many. Following the Baycol recall, consumer
advocacy group Public Citizen petitioned the FDA to include the
strongest prescription drug warning on all statin drugs to better
warn patients of the potential side effects, a point patients
have made in current Baycol litigation claiming they were unaware
of the deadly risks.
For more information on Baycol Litigation, contact
us to confer with a Baycol lawsuit lawyer.
Your Baycol Recall Information Source 